When does depot medroxyprogesterone acetate (DMPA) become effective after injection in a woman who is two months postpartum, still amenorrheic, and partially breastfeeding?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 13, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

DMPA Effectiveness After Injection at 2 Months Postpartum with Partial Breastfeeding

A woman who is 2 months postpartum, amenorrheic, and partially breastfeeding needs to abstain from sexual intercourse or use backup contraception for 7 days after receiving DMPA injection, as she does not meet the criteria for immediate effectiveness (which requires full or nearly full breastfeeding with ≥85% of feeds being breastfeeds). 1

Key Determination: Breastfeeding Status

The critical factor determining whether backup contraception is needed depends on the intensity of breastfeeding:

  • Full or nearly full breastfeeding (≥85% of feeds are breastfeeds): No backup contraception needed if <6 months postpartum and amenorrheic 1
  • Partial breastfeeding (<85% of feeds): Requires 7 days of backup contraception 1

Since this patient is partially breastfeeding, she does not qualify for the lactational amenorrhea method (LAM) protection and therefore needs backup contraception.

Timing of Contraceptive Effectiveness

Immediate Effectiveness (No Backup Needed)

DMPA provides immediate contraceptive protection without backup only when: 1

  • Started within first 7 days of menstrual bleeding, OR
  • Woman is <6 months postpartum, amenorrheic, AND fully/nearly fully breastfeeding (≥85% of feeds)

Delayed Effectiveness (7 Days Backup Required)

For all other scenarios, including this patient's situation: 1

  • Woman is ≥21 days postpartum
  • Has not experienced return of menstrual cycles
  • Does NOT meet full/nearly full breastfeeding criteria
  • Must abstain from intercourse or use additional contraception for 7 days

Mechanism Supporting 7-Day Window

The 7-day backup recommendation is based on evidence showing: 1

  • DMPA injections given within day 7 of the menstrual cycle reliably inhibit ovulation
  • When given after day 7, ovulation may occur in some women initially
  • Cervical mucus becomes poor quality (unfavorable for sperm penetration) in 90% of women within 24 hours of injection, providing partial protection 1

However, this partial protection from cervical mucus changes alone is not considered sufficient to eliminate the need for backup contraception in the first 7 days. 1

Pharmacokinetic Support

MPA is detectable in serum within 30 minutes after injection, with levels plateauing at approximately 1.0 ng/mL for about three months, providing sustained ovulation suppression. 2 Despite this rapid absorption, the 7-day backup period accounts for variability in immediate ovulation suppression among individual women. 1

Common Pitfall to Avoid

Do not assume that amenorrhea alone provides contraceptive protection in the postpartum period with partial breastfeeding. The CDC guidelines are explicit that the LAM criteria require full or nearly full breastfeeding (≥85% of feeds), and partial breastfeeding does not provide the same hormonal suppression of ovulation. 1 Return of fertility can occur before return of menses, making backup contraception essential for the first 7 days after DMPA injection in this scenario.

Practical Implementation

For this specific patient: 1

  • Administer DMPA injection at 2 months postpartum (safe timing, U.S. MEC 1 at ≥1 month postpartum)
  • Confirm reasonable certainty she is not pregnant before injection
  • Instruct patient to abstain from intercourse or use barrier contraception for 7 days after injection
  • After 7 days, DMPA provides highly effective contraception (failure rate <1% with perfect use)
  • Schedule repeat injection in 12 weeks (with 2-week grace period per U.S. recommendations) 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Pharmacokinetics of depot medroxyprogesterone acetate contraception.

The Journal of reproductive medicine, 1996

Related Questions

What is the protocol for a female wanting Depo-Provera (Medroxyprogesterone Acetate) for contraception?
What is the recommended posology of DMPA (Depot Medroxyprogesterone Acetate)?
Is it safe to administer a depo (depo medroxyprogesterone acetate (DMPA)) shot before 13 weeks postpartum?
What is the typical dosing regimen for a 20-year-old female taking Medroxyprogesterone (Provera) 10mg, Sprintec (combination oral contraceptive containing estrogen and progestin), and Lexapro (escitalopram), and how are these medications usually taken?
What is the management approach for a 17-year-old female experiencing vaginal bleeding after one dose of Depo-Provera (medroxyprogesterone acetate)?
In a 52‑year‑old obese woman with diabetes, waist circumference 125 cm, hip circumference 100 cm, and LDL‑C 4.3 mmol/L, which marker indicates the most significant health risk: LDL‑C, BMI, waist‑hip ratio, or waist circumference?
Should a patient with infective endocarditis who has an acute stroke receive antiplatelet therapy or systemic anticoagulation, and if so, what timing and dosing are recommended?
What are the advantages of magnetic resonance imaging (MRI) for evaluating recurrent sliding inguinal hernias in adults who have previously undergone hernia repair and present with persistent or recurrent groin symptoms?
What is the recommended dosing regimen, contraindications, and precautions for ketorolac injection in an adult with acute moderate-to-severe pain?
What is the appropriate management for an asymptomatic 47‑year‑old male with incidentally discovered aortic atherosclerosis and no known comorbidities?
In an adult with prior inguinal hernia repair presenting with recurrent groin symptoms, how sensitive and specific is functional provocation MRI for diagnosing recurrent sliding inguinal hernias, and is it the preferred second‑line imaging modality?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.